The company expects to recruit around 225 patients in the study to investigate the efficacy and safety of weekly injections of CJC-1134-PC for 17 weeks.
The trial also aims to evaluate the pharmacokinetic and pharmacodynamic relationship of CJC-1134-PC and glycosylated hemoglobin (HbA1c) and/or fasting plasma glucose (FPG) in the trial.
ConjuChem CEO Patrick Soon-Shiong said positive results from this study will be a vital step in the fight against diabetes.